I. Call to Order…………………………………………………………………………………Marty McKay

II. Parliamentary Business ................................................................. Marty McKay
    A. Introduction of Members/Roll Call
    B. Approval of May 4, 2016 Meeting Minutes

III. Opening Remarks…………………………………………………………SreyRam Kuy

IV. Ethics Reminders/Prohibited Political Activity......................... Kim Sullivan

V. Reports……………………………………………………………………………Melwyn Wendt
    A. Prior Authorization Monthly Report
    B. PDL Reflecting May 4, 2016 P&T Committee Recommendations

VI. New Business............................................................................ Nina Bandali
    A. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
       1. Alzheimer’s Agents
       2. Antidepressants, Other
       3. Antidepressants, SSRIs
       4. Antihistamines, Minimally Sedating
       5. Antihypertensives, Sympatholytics
       6. Antihyperuricemics
       7. Antiparkinson’s Agents
       8. Antipsoriatrics, Oral
       9. Antipsoriatrics, Topical
      10. Antipsychotics
      11. Anxiolytics
      12. Bile Salts
      13. Bronchodilators, Beta Agonist
      14. COPD Agents
      15. Cytokine and CAM Antagonists
      16. Emollients
      17. Epinephrine, Self-Injected
      18. Erythropoiesis Stimulating Proteins
      19. Glucocorticoids, Inhaled
      20. Histamine Receptor II Blocker
      21. Immunomodulators, Atopic Dermatitis
22. Immunomodulators, Topical
23. Intranasal Rhinitis Agents
24. Leukotriene Modifiers
25. Neuropathic Pain
26. NSAIDs
27. Ophthalmic, Antibiotic-Steroid Combinations
28. Ophthalmic Antibiotics
29. Ophthalmics for Allergic Conjunctivitis
30. Ophthalmics, Anti-Inflammatories
31. Ophthalmics, Glaucoma Agents
32. Otic Anti-Infectives & Anesthetics
33. Otic Antibiotics
34. Progestational Agents
35. Sedative Hypnotics
36. Smoking Cessation
37. Steroids, Topical High
38. Steroids, Topical Low
39. Steroids, Topical Medium
40. Steroids, Topical Very High
41. Stimulants and Related Agents

VII. New Single Drug Reviews.................................................................Nina Bandali
42. Angiotensin Modulator Combinations – Byvalson
43. Angiotensin Modulators – Qbrelis
44. Analgesics, Narcotics Long – Xtampza
45. Antiemetic/Antivertigo Agents – Emend Powder Packet
46. Antifungals, Topical - Loprox Kit
47. Antimigraine Agents, Triptans – Onzeta Xsail
48. Antimigraine Agents, Triptans – Zembrace Symtouch
49. Antimigraine Agents, Triptans – Migranow Kit
50. GI Motility, Chronic - Relistor
51. Hepatitis C - Viekira XR
52. Hepatitis C - Erclusa
53. Hypoglycemics, Incretin Mimetics/Enhancers – Jentadueto XR
54. Lipotropics, Other – Repatha Pushtronext
55. Multiple Sclerosis Agents – Zinbryta
56. Opiate Dependence Treatment – Probuphine
57. Tetracyclines – Doryx MPC

VIII. Other Business

VIII. Next Steps
A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – April 26, 2017

X. Public Testimony